DE&I

Senior leaders in pharma, healthcare marketing and communications, and advertising got together to discuss the progress and lingering roadblocks in advancing diversity, equity, and inclusion strategies in the life sciences—where the common thread seems clear: the messenger matters.

Developing a diversity mindset may begin at the top levels of the organization, but building diversity into the entire drug development life cycle ensures that it is an ongoing priority and a natural requirement of engaging with external stakeholders.

States and institutions are enacting mandates requiring greater inclusion of women and underrepresented groups on corporate boards; what are the key questions for pharma?

Panelists in a recent roundtable share ideas on transforming company culture, fostering greater patient diversity, and acting on pharma’s fast-evolving social mandate.

Diversity and inclusion shouldn’t be something that companies have to work hard at, writes Chris Coe.